Blood Advances (Sep 2019)

Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1

  • Celalettin Ustun,
  • Soyoung Kim,
  • Min Chen,
  • Amer M. Beitinjaneh,
  • Valerie I. Brown,
  • Parastoo B. Dahi,
  • Andrew Daly,
  • Miguel Angel Diaz,
  • Cesar O. Freytes,
  • Siddhartha Ganguly,
  • Shahrukh Hashmi,
  • Gerhard C. Hildebrandt,
  • Hillard M. Lazarus,
  • Taiga Nishihori,
  • Richard F. Olsson,
  • Kristin M. Page,
  • Genovefa Papanicolaou,
  • Ayman Saad,
  • Sachiko Seo,
  • Basem M. William,
  • John R. Wingard,
  • Baldeep Wirk,
  • Jean A. Yared,
  • Miguel-Angel Perales,
  • Jeffery J. Auletta,
  • Krishna V. Komanduri,
  • Caroline A. Lindemans,
  • Marcie L. Riches

Journal volume & issue
Vol. 3, no. 17
pp. 2525 – 2536

Abstract

Read online

Abstract: Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT–comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; P = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range, <1-99 days]; RIC/NMA, 21 days [range, <1-100 days]; P < .001). Patients receiving MAC were more likely to experience at least 1 bacterial infection by day 100 (MAC, 46% [95% confidence interval (CI), 43-49]; RIC/NMA, 37% [95% CI, 34-41]; P = .0004), whereas at least a single viral infection was more prevalent in the RIC/NMA cohort (MAC, 34% [95% CI, 31-37]; RIC/NMA, 39% [95% CI, 36-42]; P = .046). MAC remained a risk factor for bacterial infections in multivariable analysis (relative risk, 1.44; 95% CI, 1.23-1.67; P < .0001). Moreover, the rate of any infection per patient-days at risk in the first 100 days (infection density) after alloHCT was greater for the MAC cohort (1.21; 95% CI, 1.11-1.32; P < .0001). RIC/NMA was associated with reduced infections, especially bacterial infections, in the first 100 days after alloHCT.